Reporte zur Charge UI692AB

Symptomtext

patient was provided the vaccine intradermally or subcutaneously with no reported adverse event; Initial information was received on 18-Feb-2021 regarding an unsolicited valid non-serious case from a consumer or other non-professional via vaccine compensation program. This case involves a patient with unknown demographics who was provided the INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE [FLUZONE HIGH DOSE], [lot number: UI692AB, expiry date: Apr-2017] via an intradermal or a subcutaneously route at an unknown administration site on an unknown date for prophylactic vaccination (incorrect route of product administration). (Latency: on the same day) Medical history, medical treatment, vaccination family history and concomitant medication were not reported. It was a case of actual medication error due to inappropriate route of vaccination. At the time of report, no adverse event was reported. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.